Mitochondrial Dysfunction in Neurodegeneration

[1]  C. Marsden,et al.  Mitochondrial respiratory chain function in multiple system atrophy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[2]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[3]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[4]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[5]  C. Marsden,et al.  Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. , 1996, Biochemical pharmacology.

[6]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[7]  C. Marsden,et al.  Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1996, Neuroscience Letters.

[8]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[9]  M. Naoi,et al.  Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies , 1996, Brain Research.

[10]  C. W. Olanow,et al.  Manganese intoxication in the rhesus monkey , 1996, Neurology.

[11]  S. Ohta,et al.  1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.

[12]  C. Marsden,et al.  Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.

[13]  P. Allen,et al.  Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle , 1995, Neurology.

[14]  P. Carrupt,et al.  Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships. , 1995, Biochemical pharmacology.

[15]  M. Graeber,et al.  Absence of the mitochondrial A7237T mutation in Parkinson's disease. , 1995, Biochemical and biophysical research communications.

[16]  C. Marsden,et al.  L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.

[17]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[18]  M. Beal,et al.  Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease , 1994, Journal of neurochemistry.

[19]  Patrizia Mecocci,et al.  Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease , 1994, Annals of neurology.

[20]  A Hartley,et al.  Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease , 1994, Journal of neurochemistry.

[21]  B. Hyman,et al.  Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation , 1994, Journal of neuropathology and experimental neurology.

[22]  C. Marsden,et al.  A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.

[23]  H. Reichmann,et al.  Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.

[24]  B. Rosen,et al.  Malonate produces striatal lesions by indirect NMDA receptor activation , 1994, Brain Research.

[25]  Y. Mizuno,et al.  Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat , 1994, Neuroscience Letters.

[26]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[27]  E. Wolvetang,et al.  Mitochondrial respiratory chain inhibitors induce apoptosis , 1994, FEBS letters.

[28]  R. Ramsay,et al.  Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.

[29]  P. Gill,et al.  Identification of the remains of the Romanov family by DNA analysis , 1994, Nature Genetics.

[30]  O. Phillipson,et al.  1, 2, 3, 4‐Tetrahydro‐2‐Methyl‐4, 6, 7‐Isoquinolinetriol Depletes Catecholamines in Rat Brain , 1993, Journal of neurochemistry.

[31]  J. Cooper,et al.  Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. , 1993, Journal of anatomy.

[32]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[33]  J. Cooper,et al.  Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.

[34]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[35]  B T Hyman,et al.  Functional Alterations in Alzheimer's Disease: Diminution of Cytochrome Oxidase in the Hippocampal Formation , 1993, Journal of neuropathology and experimental neurology.

[36]  S. Fahn,et al.  Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.

[37]  N. Savarese,et al.  Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients , 1993, Neurology.

[38]  S. Dimauro,et al.  Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.

[39]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[40]  R. Porter,et al.  Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.

[41]  J. Cooper,et al.  Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. , 1993, American journal of human genetics.

[42]  B. Hyman,et al.  Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.

[43]  D B Calne,et al.  Progression after chronic manganese exposure , 1993, Neurology.

[44]  B. Crain,et al.  Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. , 1993, Genomics.

[45]  B. Ackrell,et al.  Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-beta-carbolines? , 1993, Biochemical Journal.

[46]  T. Chase,et al.  No evidence for altered muscle mitochondrial function in Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[47]  S. Paul,et al.  The N‐Methyl‐D‐Aspartate Antagonist MK‐801 Fails to Protect Dopaminergic Neurons from 1‐Methyl‐4‐ Phenylpyridinium Toxicity In Vitro , 1993, Journal of neurochemistry.

[48]  D. Price,et al.  Age‐Dependent Impairment of Mitochondrial Function in Primate Brain , 1993, Journal of neurochemistry.

[49]  J. Cooper,et al.  Mitochondrial function in Alzheimer's disease , 1993, The Lancet.

[50]  John Calvin Reed,et al.  Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.

[51]  E. Bertini,et al.  Fatal infantile liver failure associated with mitochondrial DNA depletion. , 1992, The Journal of pediatrics.

[52]  M. Dyer,et al.  Ultrastructural localization of bcl-2 protein. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[53]  R. Ramsay,et al.  Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piericidin A, and MPP+. , 1992, Biochemical and biophysical research communications.

[54]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[55]  A. E. Harding,et al.  Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.

[56]  J. Nobrega,et al.  Brain Cytochrome Oxidase in Alzheimer's Disease , 1992, Journal of neurochemistry.

[57]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[58]  A. Torroni,et al.  Mitochondrial oxidative phosphorylation defects in Parkinson's disease , 1992, Annals of neurology.

[59]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[60]  F. Di Virgilio,et al.  Mitochondrial DNA is not fragmented during apoptosis. , 1992, The Journal of biological chemistry.

[61]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[62]  G. Zeevalk,et al.  MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats , 1992, Journal of neurochemistry.

[63]  B. Rosen,et al.  1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism , 1992, Journal of neurochemistry.

[64]  J. Idle,et al.  Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.

[65]  C. Olanow,et al.  Iron induces degeneration of nigrostriatal neurons , 1992, Brain Research Bulletin.

[66]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[67]  J. Cooper,et al.  Quantitation of a mitochondrial DNA deletion in Parkinson's disease , 1992, FEBS letters.

[68]  J. Cooper,et al.  Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.

[69]  S. Horai,et al.  Is Parkinson's disease a mitochondrial disorder? , 1992, Journal of the Neurological Sciences.

[70]  R. Youle,et al.  Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. , 1991, Biochemical and biophysical research communications.

[71]  D. Ben-shachar,et al.  Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.

[72]  A. Tolkovsky,et al.  The Death Programme in Cultured Sympathetic Neurones Can Be Suppressed at the Posttranslational Level by Nerve Growth Factor, Cyclic AMP, and Depolarization , 1991, Journal of neurochemistry.

[73]  L. Greene,et al.  Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity , 1991, The Journal of cell biology.

[74]  T. Ozawa,et al.  Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease , 1991, Annals of neurology.

[75]  D. Turnbull,et al.  Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.

[76]  H. Pall,et al.  N-methylation of pyridines in Parkinson's disease , 1991, The Lancet.

[77]  M. Naoi,et al.  Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. , 1991, Biochemical and biophysical research communications.

[78]  K. Jellinger,et al.  Mitochondrial DNA in Postmortem Brain from Patients with Parkinson's Disease , 1991, Journal of neurochemistry.

[79]  G. Zeevalk,et al.  Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. , 1991, The Journal of pharmacology and experimental therapeutics.

[80]  K. Ohno,et al.  Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. , 1991, Biochemical and biophysical research communications.

[81]  J. Casida,et al.  Interaction of 1‐Methyl‐4‐Phenylpyridinium Ion (MPP+) and Its Analogs with the Rotenone/Piericidin Binding Site of NADH Dehydrogenase , 1991, Journal of neurochemistry.

[82]  D. D. Di Monte,et al.  Blood lactate in Parkinson's disease , 1991, Annals of neurology.

[83]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[84]  R. Ramsay,et al.  Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP+) and of the respiratory chain inhibitor piericidin A are the same. , 1991, The Biochemical journal.

[85]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[86]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[87]  K. Jellinger,et al.  Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.

[88]  T. Niwa,et al.  Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.

[89]  K. Ohno,et al.  Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. , 1990, Biochemical and biophysical research communications.

[90]  K. Davies,et al.  The oxidative inactivation of mitochondrial electron transport chain components and ATPase. , 1990, The Journal of biological chemistry.

[91]  K. Takeshige,et al.  1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.

[92]  K. Ohno,et al.  Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. , 1990, Biochemical and biophysical research communications.

[93]  F. Hefti,et al.  Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.

[94]  C. Tanner,et al.  Environmental risk factors in Parkinson's disease , 1990, Neurology.

[95]  J. Cooper,et al.  Mitochondrial myopathy with a defect of mitochondrial-protein transport. , 1990, The New England journal of medicine.

[96]  S. Ohta,et al.  Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization. , 1990, Biomedical & environmental mass spectrometry.

[97]  F. Hefti,et al.  Toxicity of 1‐Methyl‐4‐Phenylpyridinium for Rat Dopaminergic Neurons in Culture: Selectivity and Irreversibility , 1990, Journal of neurochemistry.

[98]  S. Ohta,et al.  Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease , 1990, Journal of the Neurological Sciences.

[99]  Douglas C. Miller,et al.  A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.

[100]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[101]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[102]  J A Helpern,et al.  In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia , 1989, Neurology.

[103]  K. Suzuki,et al.  Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline. , 1989, Biochemical and biophysical research communications.

[104]  R. Waring,et al.  Xenobiotic metabolism in Parkinson's disease , 1989, Neurology.

[105]  S. Dimauro,et al.  An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region , 1989, Nature.

[106]  C. Nathan,et al.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.

[107]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[108]  R. Ramsay,et al.  Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria. , 1989, Biochemical and biophysical research communications.

[109]  N. L. Rosenberg,et al.  Cyanide‐induced parkinsonism , 1989, Neurology.

[110]  Z. Rossetti,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. , 1988, Biochemical pharmacology.

[111]  L. Massieu,et al.  Relationship of Dihydropyridine Binding Sites with Calcium‐Dependent Neurotransmitter Release in Synaptosomes , 1988, Journal of neurochemistry.

[112]  A. Novelli,et al.  Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.

[113]  T. Nagatsu,et al.  An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.

[114]  J. Drapier,et al.  Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. , 1988, Journal of immunology.

[115]  Y. Mizuno,et al.  Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline , 1988, Neuroscience Letters.

[116]  D. Neary,et al.  Mitochondrial function in brain tissue in primary degenerative dementia , 1987, Brain Research.

[117]  L. Sayre,et al.  Model study on the bioreduction of paraquat, MPP+, and analogs. Evidence against a "redox cycling" mechanism in MPTP neurotoxicity. , 1987, Biochemical and biophysical research communications.

[118]  R. Uitti,et al.  Geography, Drinking Water Chemistry, Pesticides and Herbicides and the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[119]  C. Ragan,et al.  Photolabelling of a mitochondrially encoded subunit of NADH dehydrogenase with [3H]dihydrorotenone , 1987, FEBS letters.

[120]  T. Niwa,et al.  Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. , 1987, Biochemical and biophysical research communications.

[121]  C. Marsden.  Parkinson's disease in twins. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[122]  S. Ohta,et al.  Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. , 1986, Biochemical and biophysical research communications.

[123]  J. Haxby,et al.  Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. , 1986, Archives of neurology.

[124]  R. Ramsay,et al.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.

[125]  J. Haxby,et al.  Positron emission tomography in Alzheimer's disease , 1986, Neurology.

[126]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[127]  S. Markey,et al.  1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. , 1986, Life sciences.

[128]  R. Ramsay,et al.  Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.

[129]  R. Duvoisin,et al.  Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.

[130]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[131]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[132]  R. Uitti,et al.  Cyanide‐induced parkinsonism , 1985, Neurology.

[133]  J. Langston,et al.  Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? , 1985, Life sciences.

[134]  N. Castagnoli,et al.  Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.

[135]  R. Clavier,et al.  Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically , 1984, Journal of neurochemistry.

[136]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[137]  J. Bus,et al.  Paraquat: model for oxidant-initiated toxicity. , 1984, Environmental health perspectives.

[138]  C. Ward,et al.  Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.

[139]  L. Hillered,et al.  Respiratory Activity of Isolated Rat Brain Mitochondria following in vitro Exposure to Oxygen Radicals , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[140]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[141]  K. Takeshige,et al.  Alteration of inner-membrane components and damage to electron-transfer activities of bovine heart submitochondrial particles induced by NADPH-dependent lipid peroxidation. , 1982, The Biochemical journal.

[142]  C. Markham,et al.  Evidence to support early levodopa therapy in Parkinson disease , 1981, Neurology.

[143]  K. Takeshige,et al.  NADH- and NADPH-dependent formation of superoxide anions by bovine heart submitochondrial particles and NADH-ubiquinone reductase preparation. , 1979, The Biochemical journal.

[144]  T. Alston,et al.  3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[145]  B Chance,et al.  The cellular production of hydrogen peroxide. , 1972, The Biochemical journal.

[146]  F. Mettler.  Choreoathetosis and striopallidonigral necrosis due to sodium azide. , 1972, Experimental neurology.

[147]  E. Hurst.  EXPERIMENTAL DEMYELINATION OF THE CENTRAL NERVOUS SYSTEM: 3. POISONING WITH POTASSIUM CYANIDE, SODIUM AZIDE, HYDROXYLAMINE, NARCOTICS, CARBON MONOXIDE, ETC., WITH SOME CONSIDERATION OF BILATERAL NECROSIS OCCU , 1942 .

[148]  P. Jenner,et al.  Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine , 1993, Movement disorders : official journal of the Movement Disorder Society.

[149]  M. Naoi,et al.  N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. , 1993, Advances in neurology.

[150]  S. Fahn,et al.  Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line , 1993, Movement disorders : official journal of the Movement Disorder Society.

[151]  T. Chase,et al.  Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease , 1992, Movement disorders : official journal of the Movement Disorder Society.

[152]  F. Jiménez-Jiménez,et al.  Exposure to well water and pesticides in Parkinson's disease: A case‐control study in the madrid area , 1992, Movement disorders : official journal of the Movement Disorder Society.

[153]  H. Yoshino,et al.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[154]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[155]  C. Marsden,et al.  A clinical and genetic study of familial Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.

[156]  S. Hodge,et al.  Twin studies and the genetics of Parkinson's disease—a reappraisal , 1990, Movement disorders : official journal of the Movement Disorder Society.

[157]  A. Schapira,et al.  Mitochondrial DNA analysis in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[158]  N. Quinn,et al.  Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.